RT Journal
A1 Yap B, Bodney GP
T1 NEtilmicin in the treatment of infections in patients with cancer
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 1979
FD November 1
VO 139
IS 11
SP 1259
OP 1262
DO 10.1001/archinte.1979.03630480043015
UL http://dx.doi.org/10.1001/archinte.1979.03630480043015
AB Ninety-two patients with cancer with 100 infectious episodes were treated with netilmicin sulfate, a new aminoglycoside. Netilmicin was administered intravenously, either intermittently or by continuous infusion. The overall cure rate was 60%. Gram-negative bacilli were the most common causative organisms and the response rate for these infections was 32/53 (60%). The most common pathogens were Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Pneumonia, urinary tract infection, and septicemia were the most common types of infection treated and the response rates were 23/47 (49%), 19/21 (90%), and 9/17 (53%), respectively. Nephrotoxicity occurred in ten patients (6%) who had normal renal function initially. Netilmicin is an effective aminoglycoside with a spectrum of antibacterial activity similar to that of gentamicin sulfate and it appears to be less nephrotoxic.(Arch Intern Med 139:1259-1262, 1979)